NEWS: Complete Pharma PR steers Panadol drive

SmithKline Beecham is investing in a global PR push for Panadol, its biggest selling over-the-counter medicine.

SmithKline Beecham is investing in a global PR push for Panadol, its

biggest selling over-the-counter medicine.



The campaign, designed to highlight the brand’s 40-year heritage, is

being executed by Complete Pharma PR.



The agency won the business, thought to be worth over pounds 100,000 in

fees, in a non-competative pitch two weeks ago. Its brief is to co

ordinate PR with SmithKline Beecham’s worldwide agencies, targeting

trade, consumer and health professionals.



Dr Marion Wellwood, SmithKline Beecham’s director of medical

communications, said details were still being finalised but the PR drive

will focus on Panadol’s history and unveil new data pointing to its

future uses.



She added that the campaign may tackle the reported issue of Panadol

being used in overdoses in the UK but said that, ‘as with other popular

brands, the issue crops up but it is not a particular problem’.



Panadol is the market leading analgesic in around 30 countries except

the UK and the US where Anadin and Johnson and Johnson’s brand Tylenol,

respectively, have the lion’s share. It also competes with asprin and

ibuprofen products and increasingly, own label analgesics.



‘It’s our biggest product but still has a long way to go,’ said

Wellwood.



Complete Pharma already handles PR for SmithKline Beecham’s hepatitis B

vaccine Enegerix-B, antibiotic Augmentin and Paxil, a prozac-style drug

for the treatment of panic disorder.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in